4BB4

ephB4 kinase domain inhibitor complex

4BB4 の概要

• エントリーDOI: 10.2210/pdb4bb4/pdb
• 関連するPDBエントリー: 2BBA 2VWU 2VWV 2VWW 2VWX 2VWY 2VWZ 2VX0 2VX1 2X9F 2XVD 4AW5
• 分子名称: EPHRIN TYPE-B RECEPTOR 4, N-(2-methoxyethyl)-4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide, MAGNESIUM ION, ... (4 entities in total)
• 機能のキーワード: transferase, unphosphorylated
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 34382.87

構造登録者

Read, J.,Brassington, C.A.,Green, I.,McCall, E.J.,Valentine, A.L. (登録日: 2012-09-19, 公開日: 2013-02-27, 最終更新日: 2024-05-08)

主引用文献

Vasbinder, M.M.,Aquila, B.,Augustin, M.,Chen, H.,Cheung, T.,Cook, D.,Drew, L.,Fauber, B.P.,Glossop, S.,Grondine, M.,Hennessy, E.J.,Johannes, J.,Lee, S.,Lyne, P.D.,Mortl, M.,Omer, C.,Palakurthi, S.,Pontz, T.,Read, J.,Sha, L.,Shen, M.,Steinbacher, S.,Wang, H.,Wu, A.,Ye, M.
Discovery and Optimization of a Novel Series of Potent Mutant B-Raf V600E Selective Kinase Inhibitors.
J.Med.Chem., 56:1996-, 2013

PubMed Abstract: B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf(V600E) kinase activity both in vitro and in vivo. Investigations into the structure-activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and pharmacokinetic profile. Compounds selectively inhibited B-Raf(V600E) in vitro and showed preferential antiproliferative activity in mutant B-Raf(V600E) cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-Raf(V600E) A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro.

PubMed: 23398453
DOI: 10.1021/JM301658D

実験手法

X-RAY DIFFRACTION (1.65 Å)